Vistagen Therapeutics (VTGN) Free Cash Flow (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Free Cash Flow of -$16.2 million for Q1 2026, up 8.67% sequentially from -$17.7 million in Q4 2025, and down 62.67% YoY from -$43.4 million in Q1 2025.
Vistagen Therapeutics (VTGN) Free Cash Flow (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Free Cash Flow for 17 years, with the latest figure at -$16.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 62.67% year-over-year to -$16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.6 million (down 58.09% YoY) and the FY2026 annual result came in at -$66.4 million, down 57.73% from the prior year.
- Free Cash Flow climbed to -$16.2 million in Q1 2026 per VTGN's latest filing, from -$17.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$4.8 million in Q4 2023 and troughed at -$18.9 million in Q2 2025.
- A 5-year average of -$11.8 million and a median of -$10.8 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 189.94% in 2022, then jumped 62.18% in 2023.
- Over 5 years, Free Cash Flow stood at -$9.7 million in 2022, then soared by 51.05% to -$4.8 million in 2023, then sank by 117.9% to -$10.4 million in 2024, then tumbled by 70.84% to -$17.7 million in 2025, then climbed by 8.67% to -$16.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$16.2 million, -$17.7 million, and -$13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | -14.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.20 Mn |
| Mar 31, 2026 | -16.20 Mn |
| Dec 31, 2025 | -17.74 Mn |
| Dec 31, 2025 | -17.74 Mn |
| Sep 30, 2025 | -13.75 Mn |
| Sep 30, 2025 | -13.75 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Jun 30, 2025 | -18.87 Mn |
| Mar 31, 2025 | -9.96 Mn |
| Mar 31, 2025 | -9.96 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -10.81 Mn |
| Sep 30, 2024 | -10.81 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Mar 31, 2024 | -7.00 Mn |
| Mar 31, 2024 | -7.00 Mn |
| Dec 31, 2023 | -4.77 Mn |
| Dec 31, 2023 | -4.77 Mn |